Latest News and Press Releases

Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data...

Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary Trial advanced to second stage to...

Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific...

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...

Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28.75M initial public offering and $31.25M private...

PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...

PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...

PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...

Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented ...